U.S. Sex Reassignment Hormone Therapy Market
Updated Date: 20 July 2026   |   Report Code: 6812
sales@towardshealthcare.com +1 804-441-9344
Download Sample Order Now

US Sex Reassignment Hormone Therapy Market Size, Growth & Forecast 2035

According to Payal Rabde, who specializes in LGBTQ+ specialized healthcare services, integrated mental health and gender-affirming care, and hormone monitoring and dose optimization, with 4+ years of experience in market research and industry analysis, extensive research indicates strong growth opportunities in the U.S. sex reassignment hormone therapy market. The global U.S. sex reassignment hormone therapy market size was estimated at USD 1.3 billion in 2025 and is predicted to increase from USD 1.39 billion in 2026 to approximately USD 2.61 billion by 2035, expanding at a CAGR of 7.2% from 2026 to 2035. Her analysis highlights the increasing adoption of telehealth-based hormone therapy services, AI-enabled hormone dose monitoring and management, precision endocrinology approaches, multidisciplinary gender-affirming care, continuous hormone monitoring and laboratory testing, long-acting injectable hormone, and transdermal hormone patches and gels. The research also examines the competitive strategies of key industry participants, including AbbVie, Pfizer, RO, CVS Health, Plume, Planned Paraenthood of Greater New York, and Fenway Health shaping the future by comprehensive multidisciplinary gender-affirming care models, wearable health monitoring for therapy management, health record integration for continuity of care, patient-centerd, accessible hormone therapy services, innovation in next-generation hormone formulations and delivery systems, and digital health hormone dose optimization and clinical decision support in the global U.S. sex reassignment hormone therapy market.

Last Updated : 20 July 2026 Category: Therapeutic Area Insight Code: 6812 Format: PDF / PPT / Excel

Content

Chapter 1: Introduction

  • Market Definition & Taxonomy
  • Research Objectives
  • Market Scope & Assumptions
  • Study Timeline (Historical, Base Year, Forecast Period)
  • Key Stakeholders Covered

Chapter 2: Research Methodology

  • Research Framework Overview
  • Market Size Estimation Methodology
    • Bottom-Up Approach
    • Top-Down Approach
  • Forecasting Model
    • Dependent Variables
    • Independent Variables
    • Key Assumptions & Weightages
  • Primary Research Insights
  • Secondary Data Sources
  • Data Validation & Triangulation

Chapter 3: Executive Summary

  • Global & Regional Overview (Value, CAGR)
  • Epidemiology Snapshot
  • Segmental Overview
  • Competition Key Snippets
  • Strategic Takeaways

Chapter 4: Market Catalysts, Constraints & Growth Levers

  • Market Dynamics
  • Market Drivers/Catalysts
    • Driver 1
    • Driver 2
  • Market Restraints
    • Restraint 1
    • Restraint 2
  • Market Opportunities
    • Opportunity 1
    • Opportunity 2
  • Market Trends
    • Trend 1
    • Trend 2
  • Impact Assessment of Drivers, Restraints, Opportunities & Trends (High, Mid, & Low)

Chapter 5: Value Added Intelligence

  • Porter’s Five Forces Analysis
    • Bargaining Power of Suppliers: Low/Moderate/High
    • Bargaining Power of Buyers: Low/Moderate/High
    • Threat of New Entrants: Low/Moderate/High
    • Threat of Substitute: Low/Moderate/High
    • Competitive Rivalry: Low/Moderate/High
  • PESTEL Analysis
  • Ecosystem Analysis
  • Mapping of Key Players
  • Value Chain Analysis
  • Margin Analysis Across Value Chain
  • Macro & Micro Factors Impacting Market
  • Market Potential Evaluation, By Region
  • Epidemiology & Patient Pool Analysis
    • Disease Incidence & Prevalence
    • Target Patient Pool
      • Diagnosed Population
      • Service-Seeking Population
    • Patient Flow & Utilization Analysis
      • Patient Footfall
      • Admission Rates
      • Procedure Volume
    • Healthcare Infrastructure Analysis
      • Number of Facilities
        • Hospitals
        • Clinics
        • Diagnostic Centers
        • ASCs
      • Bed Capacity
        • Total Beds
        • ICU Beds
      • Facility Distribution
    • Operational Metrics Analysis
      • Bed Occupancy Rate (%)
      • Average Length of Stay (ALOS)
    • Service Pricing & Revenue Model
      • Pricing Analysis
        • Cost per Procedure
        • Cost per Consultation
        • Cost per Diagnostic Test
      • Revenue Streams
        • Inpatient Services
        • Outpatient Services
        • Ancillary Services
      • Workforce & Staffing Analysis
        • Healthcare Workforce
          • Physicians
          • Nurses
          • Technicians
        • Staff-to-Patient Ratios
        • Skill Gap Analysis
        • Labor Cost Structure
      • Scenario Analysis (Base / Optimistic / Pessimistic)
      • Risk Assessment & Sensitivity Analysis
      • Opportunity Analysis, By Region
      • Regulatory Analysis
      • Sustainability & ESG Insights
      • Business Models
      • Investment & Funding Landscape
      • Key Conferences and Events

Chapter 7: Segmental & Regional Analysis

  • Global U.S. Sex Reassignment Hormone Therapy Market Analysis, By Hormone Type
    • Market Size, Forecast & CAGR, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Sex Reassignment Hormone Therapy Market Analysis, By Gender Category
    • Market Size, Forecast & CAGR, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Sex Reassignment Hormone Therapy Market Analysis, By Route of Administration
    • Market Size, Forecast & CAGR, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Sex Reassignment Hormone Therapy Market Analysis, By Distribution Channel
    • Market Size, Forecast & CAGR, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Sex Reassignment Hormone Therapy Market Analysis, By End User
    • Market Size, Forecast & CAGR, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • Global U.S. Sex Reassignment Hormone Therapy Market Analysis, By Region
    • Market Size, Forecast & CAGR, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis, By Gender Category, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis, By Route of Administration, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis, By Distribution Channel, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis, By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
  • North America U.S. Sex Reassignment Hormone Therapy Market Analysis, By Country, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
      • U.S. U.S. Sex Reassignment Hormone Therapy Market Analysis
    • U.S. U.S. Sex Reassignment Hormone Therapy Market Analysis, By Hormone Type, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Sex Reassignment Hormone Therapy Market Analysis, By Gender Category, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Sex Reassignment Hormone Therapy Market Analysis, By Route of Administration, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Sex Reassignment Hormone Therapy Market Analysis, By Distribution Channel, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis
    • U.S. U.S. Sex Reassignment Hormone Therapy Market Analysis,By End User, 2022-2035
    • Key Rationale
    • Y-o-Y Analysis

Similar Analysis will be given for each country and each region

  • Canada
  • Mexico
  • Rest of North America

Europe

  • Western Europe
  • Germany
  • Italy
  • France
  • Spain
  • UK
  • Netherlands
  • Switzerland
  • Nordic Countries
  • Rest of Western Europe
  • Eastern Europe
  • Austria
  • Russia & Belarus
  • Poland
  • Türkiye
  • Rest of Eastern Europe

Asia Pacific

  • China
  • Taiwan
  • India
  • Japan
  • Vietnam
  • Australia and New Zealand
  • ASEAN Countries
  • South Korea
  • Rest of APAC

South America

  • Brazil
  • Argentina
  • Rest of South America

Middle East and Africa (MEA)

  • GCC Countries
  • South Africa
  • Egypt
  • Rest of MEA

Chapter 6: Competitive Insights

  • Competitive Analysis
    • Company Evaluation Matrix
      • Major Players
      • Mid-Sized Companies
      • Emerging Players/Start-Ups
    • Global Market Share Analysis, By Region, 2025 (%)
    • Key Player Positioning
    • Competitive Benchmarking
      • By Hormone Type
      • By Gender Category
      • By Route of Administration
      • By Distribution Channel
      • By End User
    • Strategies of Key Players
    • Insight From the Horse’s Mouth
  • Company Profiles
    • Viatris Inc.
      • Company Name
      • Company Headquarters
      • Management Overview
        • Key C-Suite Executives
          • CEO
          • MD
          • Others
        • Employee Count
        • Business Strategy
          • Key Investments Made
          • Future Plans
          • R&D & Innovation Capabilities
          • Recent Developments
            • New Product Launch
            • Merger & Acquisitions
            • Partnerships & Collaborations
            • Market Expansion
            • Others
          • Service Portfolio
          • Facility Network
            • Number of Facilities
            • Bed Capacity
            • Facility Distribution
            • Expansion Pipeline
          • Key Financials (2022-2025)
            • Revenue By Segment
            • Revenue By Service
            • Revenue By Geography
            • Financial Matrix (Gross Profit Margins, Net Margins, etc.)
          • Key Clients
            • Client Company Name
            • Key Contact Person
            • Contact Details
          • Regulatory & Certification Expertise
          • SWOT Analysis
    • AbbVie Inc.
    • Pfizer Inc.
    • ASCEND Therapeutics US, LLC.
    • Novartis AG

FAQ's

Answer : The U.S. sex reassignment hormone therapy market in 2026 is valued at USD 1.39 billion and is projected to climb to USD 2.61 billion by 2035, with a CAGR of 7.2% over the forecast period.

Answer : Ministry of Health and Family Welfare, Government of India, National Institutes of Health, FDA, WHO, PIB, CDC.
Any Questions

Meet the Team

Payal Rabde is a Healthcare Market Research Analyst at Towards Healthcare Research & Consulting with 4+ years of experience in pharmaceuticals, biotechnology, medical devices, and life sciences.

Learn more about Payal Rabde

Aditi Shivarkar is a seasoned professional with over 14 years of experience in healthcare market research. As a content reviewer, Aditi ensures the quality and accuracy of all market insights and data presented by the research team.

Learn more about Aditi Shivarkar